Evidence map›Paper›PMID 40947689›Full record

ReviewMedicinal chemistry (Shariqah (United Arab Emirates))2026

Recent Advances in Synthetic Pathways and Therapeutic Potential of Acridine and Acridone Derivatives.

Kalyani Asraji Dalvi, Sarita Suryabhan Pawar

Abstract readReview
PubMed Publisher
In one paragraph

Review in Medicinal chemistry (Shariqah (United Arab Emirates)), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Kalyani Asraji DalviDepartment of Pharmaceutical Chemistry, Sanjivani College of Pharmaceutical Education and Research, Kopargaon, Maharashtra, India.ORCID 0000-0001-5090-8955
Sarita Suryabhan PawarDepartment of Pharmaceutical Chemistry, Sanjivani College of Pharmaceutical Education and Research, Kopargaon, Maharashtra, India.ORCID 0000-0001-5264-157X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer, bacterial, parasitic, viral, and neurological diseases like Alzheimer's continue to pose serious health risks around the world. We need new therapeutic agents that are more targeted, effective, and safer. Because of their wide range of biological actions, acridine and its derivatives have become increasingly popular among the numerous intriguing chemical classes. Over time, several synthetic analogs of these substances have shown great promise, exhibiting noteworthy antitumor properties (e.g., N-(2-(dimethylamino) ethyl) acridine-4-carboxamide (DACA) and triazole acridone (C-1305)), as well as strong antimicrobial (e.g., 4-amino-N-[amino(imino) methyl]-benzene sulphonamide), antiviral (e.g., derivatives of acridine sulphonamide), and anti- Alzheimer's (e.g., Citrusinine-I) properties. These substances have therapeutic potential, but side effects frequently prevent them from being used in clinical settings. This review discusses all the new developments in acridine and acridone derivatives since 2024. It focuses on how they are made and might be used in medicine. By shedding light on these innovations, the study aims to offer a fresh perspective on their role in shaping the future of medicinal chemistry and drug development. This work's main goal is to investigate and evaluate the most current progress in the synthesis as well as biological uses concerning derivatives of acridine along with acridone, especially those that have been published after 2024. The target of the study is to demonstrate the compounds' medicinal perspective by highlighting their antiviral, anticancer, antibacterial, and anti-Alzheimer effects. Furthermore, the research aims to tackle the difficulties related to their adverse effects, offering valuable perspectives for the creation of safer and more efficient medications in the field of medicinal chemistry in the future.

Indexed as

AcridinesAcridonesAntineoplastic AgentsAnimalsAnti-Infective AgentsAntiviral AgentsHumansAcridinesacridoneAcridonesAnti-Infective AgentsAntineoplastic AgentsAntiviral AgentsAcridineanticancerDNA targeting drugsprotein kinase inhibitor.synthesistelomerase inhibitortopoisomerase inhibitor

Identifiers

PMID40947689

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.